We have located links that may give you full text access.
Anti-phospholipid IgG antibodies detected by line immunoassay differentiate patients with anti-phospholipid syndrome and other autoimmune diseases.
Auto- Immunity Highlights 2018 May 30
PURPOSE: Anti-phospholipid antibodies (aPL) analyzed by line immunoassay (LIA) can recognize beta2 -glycoprotein I (β2 GPI) domain 1 (D1) epitopes depending on β2 GPI binding to distinct phospholipids. The aPL LIA was compared with consensus ELISA to investigate whether both techniques can discriminate anti-phospholipid syndrome (APS) patients from aPL-positive, systemic autoimmune rheumatic diseases (SARD) patients without clinical symptoms of APS and controls.
METHODS: Thirty-four APS patients (14 arterial/venous thrombosis, 16 pregnancy morbidity, and 4 both), 41 patients with SARD lacking clinical APS criteria but demonstrating positivity for anti-β2 GPI (aβ2 GPI) IgG, and 20 healthy subjects (HS) were tested for aPL to cardiolipin (aCL), phosphatidic acid, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol (aPG), phosphatidylinositol, phosphatidylserine, β2 GPI, prothrombin, and annexin V by LIA. Samples were also tested for aCL, aβ2 GPI, aβ2 GPI-domain 1 (aD1), and aβ2 GPI-domains 4-5 (aD4-5) by ELISA and for lupus anti-coagulant.
RESULTS: Comparison of LIA with ELISA revealed a good agreement for the consensus criteria aPL aβ2 GPI and aCL IgG (kappa = 0.69, 0.68, respectively) and a moderate agreement for IgM (kappa = 0.52, 0.49, respectively). Regarding ELISA, aD1/aD4-5 demonstrated the best performance of differentiating APS from asymptomatic SARD [area under the curve (AUC): 0.76]. aPG IgG had the best performance by LIA (AUC: 0.72) not significantly different from aD1/aD4-5. There was a good agreement for aPG IgG with aD1/aD4-5 (kappa = 0.71).
CONCLUSIONS: aD1/aD4-5 (ELISA) and aPG IgG (LIA) differentiate APS from SARD patients. PG appears to interact with β2 GPI of APS patients and exposes D1 thereof for disease-specific aPL binding in LIA.
METHODS: Thirty-four APS patients (14 arterial/venous thrombosis, 16 pregnancy morbidity, and 4 both), 41 patients with SARD lacking clinical APS criteria but demonstrating positivity for anti-β2 GPI (aβ2 GPI) IgG, and 20 healthy subjects (HS) were tested for aPL to cardiolipin (aCL), phosphatidic acid, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol (aPG), phosphatidylinositol, phosphatidylserine, β2 GPI, prothrombin, and annexin V by LIA. Samples were also tested for aCL, aβ2 GPI, aβ2 GPI-domain 1 (aD1), and aβ2 GPI-domains 4-5 (aD4-5) by ELISA and for lupus anti-coagulant.
RESULTS: Comparison of LIA with ELISA revealed a good agreement for the consensus criteria aPL aβ2 GPI and aCL IgG (kappa = 0.69, 0.68, respectively) and a moderate agreement for IgM (kappa = 0.52, 0.49, respectively). Regarding ELISA, aD1/aD4-5 demonstrated the best performance of differentiating APS from asymptomatic SARD [area under the curve (AUC): 0.76]. aPG IgG had the best performance by LIA (AUC: 0.72) not significantly different from aD1/aD4-5. There was a good agreement for aPG IgG with aD1/aD4-5 (kappa = 0.71).
CONCLUSIONS: aD1/aD4-5 (ELISA) and aPG IgG (LIA) differentiate APS from SARD patients. PG appears to interact with β2 GPI of APS patients and exposes D1 thereof for disease-specific aPL binding in LIA.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app